Xeris Biopharma Holdings, Inc. (XERS)
NASDAQ · Manufacturing · Pharmaceutical preparations
$9.06+$0.1100 (+1.23%) on the dayAs of the close; data may be delayed.
XERS price, last 12 months
Key stats
- Previous close
- $8.95
- Open
- $8.85
- Day range
- $8.78 – $9.15
- 52-week range
- $5.25 – $10.08
- Volume
- 1.3M
- Avg volume (20 days)
- 1.9M
- Market cap
- $1.7B
Performance
1W+10.5%
1M+4.4%
3M+17.8%
6M+62.7%
YTD+15.4%
1Y+13.3%
vs S&P 500, 1Y−3.5 pts
Technicals and fundamentals
About Xeris Biopharma Holdings, Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $1.7B